Clinical experience with daptomycin in Europe: the first 2.5 years

To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. Data from the European Cubicin Outcomes Registry and Experience (EU-CORESM), retrospectively collected at 118 institutions between January 2006 and August 2008, were analyse...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2011-04, Vol.66 (4), p.912-919
Main Authors: GONZALEZ-RUIZ, Armando, BEIRAS-FERNANDEZ, Andres, LEHMKUHL, Hans, ANDREW SEATON, R, LOEFFLER, Juergen, CHAVES, Ricardo L
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Child
Child, Preschool
Daptomycin - adverse effects
Daptomycin - therapeutic use
Enterococcus faecium
Enterococcus faecium - drug effects
Enterococcus faecium - isolation & purification
Europe
Female
Gram-positive bacteria
Gram-Positive Bacterial Infections - drug therapy
Gram-Positive Bacterial Infections - microbiology
Humans
Infant
Male
Medical sciences
Medical treatment
Middle Aged
Original Research
Pharmacology. Drug treatments
Retrospective Studies
Staphylococcus - drug effects
Staphylococcus - isolation & purification
Staphylococcus aureus
Staphylococcus infections
Tissues
Toxicity
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. Data from the European Cubicin Outcomes Registry and Experience (EU-CORESM), retrospectively collected at 118 institutions between January 2006 and August 2008, were analysed. Daptomycin treatment was documented in 1127 patients with diverse infections, including complicated skin and soft tissue infections (33%), bacteraemia (22%), endocarditis (12%) and osteomyelitis (6%). It was used empirically, before microbiological results became available, in 53% of patients. Staphylococcus aureus was the most common pathogen (34%), with 52% of isolates resistant to methicillin; coagulase-negative staphylococci and enterococci were also frequent, with 22% of Enterococcus faecium isolates resistant to vancomycin. Daptomycin was used as first-line therapy in 302 (27%) patients. When used second line, the most common reasons for discontinuation of previous antibiotic were treatment failure and toxicity or intolerance. The use of concomitant antibiotics was reported in 65% of patients. Most frequent doses were 6 mg/kg (47%) and 4 mg/kg (32%). The median duration of daptomycin therapy was 10 days (range 1-246 days) in the inpatient setting and 13 days (range 2-189 days) in the outpatient setting. The overall clinical success rate was 79%, with a clinical failure rate of
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkq528